|
Gene: F11 |
Gene summary for F11 |
Gene summary. |
Gene information | Species | Human | Gene symbol | F11 | Gene ID | 2160 |
Gene name | coagulation factor XI | |
Gene Alias | FXI | |
Cytomap | 4q35.2 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P03951 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2160 | F11 | NAFLD1 | Human | Liver | NAFLD | 3.39e-09 | 8.29e-01 | -0.04 |
2160 | F11 | S41 | Human | Liver | Cirrhotic | 2.97e-02 | 3.45e-01 | -0.0343 |
2160 | F11 | S43 | Human | Liver | Cirrhotic | 9.43e-06 | -1.35e-01 | -0.0187 |
2160 | F11 | HCC1_Meng | Human | Liver | HCC | 1.63e-19 | -1.91e-01 | 0.0246 |
2160 | F11 | HCC2_Meng | Human | Liver | HCC | 1.05e-09 | -2.27e-01 | 0.0107 |
2160 | F11 | cirrhotic2 | Human | Liver | Cirrhotic | 3.54e-03 | -1.78e-01 | 0.0201 |
2160 | F11 | HCC2 | Human | Liver | HCC | 6.20e-06 | 3.36e+00 | 0.5341 |
2160 | F11 | Pt14.d | Human | Liver | HCC | 4.93e-02 | -1.87e-01 | 0.0143 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004440920 | Oral cavity | OSCC | entry into host | 86/7305 | 151/18723 | 5.74e-06 | 6.37e-05 | 86 |
GO:00358218 | Oral cavity | OSCC | modulation of process of other organism | 64/7305 | 106/18723 | 6.70e-06 | 7.36e-05 | 64 |
GO:19011847 | Oral cavity | OSCC | regulation of ERBB signaling pathway | 50/7305 | 79/18723 | 1.06e-05 | 1.12e-04 | 50 |
GO:00518517 | Oral cavity | OSCC | modulation by host of symbiont process | 40/7305 | 60/18723 | 1.32e-05 | 1.33e-04 | 40 |
GO:000961210 | Oral cavity | OSCC | response to mechanical stimulus | 115/7305 | 216/18723 | 1.43e-05 | 1.44e-04 | 115 |
GO:002240718 | Oral cavity | OSCC | regulation of cell-cell adhesion | 218/7305 | 448/18723 | 1.71e-05 | 1.68e-04 | 218 |
GO:003410919 | Oral cavity | OSCC | homotypic cell-cell adhesion | 55/7305 | 90/18723 | 1.78e-05 | 1.73e-04 | 55 |
GO:004671820 | Oral cavity | OSCC | viral entry into host cell | 81/7305 | 144/18723 | 1.98e-05 | 1.89e-04 | 81 |
GO:000206419 | Oral cavity | OSCC | epithelial cell development | 116/7305 | 220/18723 | 2.34e-05 | 2.21e-04 | 116 |
GO:00063522 | Oral cavity | OSCC | DNA-templated transcription, initiation | 74/7305 | 130/18723 | 2.56e-05 | 2.39e-04 | 74 |
GO:00420587 | Oral cavity | OSCC | regulation of epidermal growth factor receptor signaling pathway | 46/7305 | 73/18723 | 2.80e-05 | 2.59e-04 | 46 |
GO:00705344 | Oral cavity | OSCC | protein K63-linked ubiquitination | 37/7305 | 56/18723 | 3.74e-05 | 3.32e-04 | 37 |
GO:00421804 | Oral cavity | OSCC | cellular ketone metabolic process | 111/7305 | 211/18723 | 3.94e-05 | 3.45e-04 | 111 |
GO:005101720 | Oral cavity | OSCC | actin filament bundle assembly | 86/7305 | 157/18723 | 4.28e-05 | 3.70e-04 | 86 |
GO:00063792 | Oral cavity | OSCC | mRNA cleavage | 18/7305 | 22/18723 | 5.05e-05 | 4.23e-04 | 18 |
GO:00072669 | Oral cavity | OSCC | Rho protein signal transduction | 76/7305 | 137/18723 | 6.64e-05 | 5.37e-04 | 76 |
GO:006157220 | Oral cavity | OSCC | actin filament bundle organization | 87/7305 | 161/18723 | 7.49e-05 | 5.84e-04 | 87 |
GO:00018859 | Oral cavity | OSCC | endothelial cell development | 40/7305 | 64/18723 | 1.20e-04 | 8.57e-04 | 40 |
GO:00160537 | Oral cavity | OSCC | organic acid biosynthetic process | 155/7305 | 316/18723 | 1.64e-04 | 1.13e-03 | 155 |
GO:19011858 | Oral cavity | OSCC | negative regulation of ERBB signaling pathway | 23/7305 | 32/18723 | 1.67e-04 | 1.14e-03 | 23 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
F11R | F11R | F11R_F11R | JAM | Breast | ADJ |
JAM2 | F11R | JAM2_F11R | JAM | Breast | ADJ |
JAM3 | F11R | JAM3_F11R | JAM | Breast | ADJ |
F11R | F11R | F11R_F11R | JAM | Breast | DCIS |
JAM2 | F11R | JAM2_F11R | JAM | Breast | DCIS |
JAM3 | F11R | JAM3_F11R | JAM | Breast | DCIS |
F11R | F11R | F11R_F11R | JAM | Breast | IDC |
F11R | F11R | F11R_F11R | JAM | Breast | Precancer |
F11R | F11R | F11R_F11R | JAM | Cervix | ADJ |
JAM2 | F11R | JAM2_F11R | JAM | Cervix | ADJ |
F11R | F11R | F11R_F11R | JAM | Cervix | CC |
JAM2 | F11R | JAM2_F11R | JAM | Cervix | CC |
JAM3 | F11R | JAM3_F11R | JAM | Cervix | CC |
F11R | F11R | F11R_F11R | JAM | Cervix | Precancer |
JAM2 | F11R | JAM2_F11R | JAM | Cervix | Precancer |
JAM3 | F11R | JAM3_F11R | JAM | Cervix | Precancer |
F11R | F11R | F11R_F11R | JAM | CRC | AD |
JAM2 | F11R | JAM2_F11R | JAM | CRC | AD |
JAM3 | F11R | JAM3_F11R | JAM | CRC | AD |
F11R | F11R | F11R_F11R | JAM | CRC | ADJ |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F11 | SNV | Missense_Mutation | rs866758594 | c.1565G>A | p.Arg522Lys | p.R522K | P03951 | protein_coding | tolerated(0.42) | benign(0.125) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F11 | SNV | Missense_Mutation | c.1597N>A | p.Gln533Lys | p.Q533K | P03951 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
F11 | SNV | Missense_Mutation | rs374606272 | c.550N>A | p.Val184Met | p.V184M | P03951 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
F11 | deletion | Frame_Shift_Del | novel | c.1343delN | p.Leu449Ter | p.L449* | P03951 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
F11 | SNV | Missense_Mutation | rs763496524 | c.802N>T | p.Arg268Cys | p.R268C | P03951 | protein_coding | tolerated(0.18) | probably_damaging(0.967) | TCGA-EK-A3GN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
F11 | SNV | Missense_Mutation | novel | c.673N>T | p.Val225Phe | p.V225F | P03951 | protein_coding | tolerated(0.08) | probably_damaging(0.993) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
F11 | SNV | Missense_Mutation | c.1641N>C | p.Lys547Asn | p.K547N | P03951 | protein_coding | tolerated(0.21) | benign(0.044) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
F11 | SNV | Missense_Mutation | c.760C>A | p.Leu254Ile | p.L254I | P03951 | protein_coding | deleterious(0.05) | possibly_damaging(0.795) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
F11 | SNV | Missense_Mutation | c.1003N>A | p.Ala335Thr | p.A335T | P03951 | protein_coding | tolerated(0.68) | benign(0.054) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
F11 | SNV | Missense_Mutation | c.913N>A | p.Glu305Lys | p.E305K | P03951 | protein_coding | deleterious(0.02) | benign(0.235) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | ANTITHROMBIN | |||
2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | THROMBIN | THROMBIN | 9787166 | |
2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | DEXTRAN SULFATE | 12968031 | ||
2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | hormonal contraceptives for systemic use | 28750087 | ||
2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | EP-7041 | |||
2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | ISIS-FXIRX | |||
2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 178103163 | ||
2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | SULFATED PENTAGALLOYLGLUCOSIDE | SULFATED PENTAGALLOYLGLUCOSIDE | 23316863 |
Page: 1 |